News|Videos|October 26, 2026

PharmTech Weekly Roundup—October 23, 2026: CMC Considerations, Rare Disease Development, Standards Harmonization

Author(s)Susan Haigney

This week on PharmTech.com, experts discussed E&L suitability standards, rare disease treatment development, sourcing ingredient suppliers, the use of AI in quality control, and more.

The use of artificial intelligence (AI) is all aspects of pharmaceutical development and manufacturing was once again a hot topic on PharmTech.com this week, with both headline news and our experts weighing in on the technology’s progress. AI factored into a common theme of “keeping things on schedule”, from FDA’s expedited pathways and new approvals to AI agents built to keep drug programs on track. But to keep up the pace, manufacturing must be able to scale new modalities, analytical data labs must be able to trust data, and quality teams must be ready for new tools.

Related to this article

white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.